NCB-02 (standardized Curcumin Preparation) Protects Dinitrochlorobenzene- Induced Colitis Through Down-regulation of NFkappa-B and INOS

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2007 Mar 22

PMID 17373747

Citations 21

Authors

M V Venkataranganna

Md Rafiq

S Gopumadhavan

Ghouse Peer

U V Babu

S K Mitra

Affiliations

Soon will be listed here.

Abstract

Aim: To evaluate the efficacy and mechanism of action of NCB 02, a standardized Curcumin preparation, against 2, 4 dinitrochlorobenzene (DNCB) induced ulcerative colitis in rats.

Methods: Ulcerative colitis was induced in male rats by sensitizing with topical application of DNCB in acetone for 14 d and intra-colonol challenge with DNCB on day 15. A separate group of animals with vehicle treatment in similar fashion served as control group. Colitis rats were divided into different groups and treated with NCB-02 at doses of 25, 50 and 100 mg/kg b.wt p.o. for 10 d. Sulfasalazine at a dose of 100 mg/kg b.wt for 10 d served as a reference group. On day 10 after respective assigned treatment, all the animals were euthanized and the length of the colon, weight of entire colon and distal 8 cm of the colon were recorded. The distal part of the colon was immediately observed under a stereomicroscope and the degree of damage was scored. Further distal 8 cm of the colon was subject to the determination of colonic myeloperoxidase (MPO), lipid peroxidation (LPO) and alkaline phosphatase (ALP) activities. A small piece of the sample from distal colon of each animal was fixed in 10% neutral buffered formalin and embedded in paraffin wax and sectioned for immunohistochemical examination of NFkappa-B and iNOS expression.

Results: NCB-02 showed a dose dependent protection against DNCB-induced alteration in colon length and weight. NCB-02 treatment also showed a dose dependent protection against the elevated levels of MPO, LPO and ALP, induced by DNCB. NCB-02 demonstrated a significant effect at a dose of 100 mg/kg b.wt., which was almost equipotent to 100 mg/kg b.wt. of sulfasalazine. Treatment with sulfasalazine and curcumin at a dose of 100 mg/kg b.wt. inhibited the DNCB-induced overexpression of NFkappa-B and iNOS in the colon.

Conclusion: Curcumin treatment ameliorates colonic damage in DNCB induced colitic rats, an effect associated with an improvement in intestinal oxidative stress and downregulation of colonic NFkappa-B and iNOS expression.

Citing Articles

Oral enzyme-responsive nanoprobes for targeted theranostics of inflammatory bowel disease.

Cao L, Duan D, Peng J, Li R, Cao Q, Li X J Nanobiotechnology. 2024; 22(1):484.

PMID: 39138477 PMC: 11321179. DOI: 10.1186/s12951-024-02749-1.

Phytochemicals and Regulation of NF-kB in Inflammatory Bowel Diseases: An Overview of In Vitro and In Vivo Effects.

Fornari Laurindo L, de Oliveira Dos Santos A, de Carvalho A, Bechara M, Landgraf Guiguer E, de Alvares Goulart R Metabolites. 2023; 13(1).

PMID: 36677021 PMC: 9862976. DOI: 10.3390/metabo13010096.

Biodistribution and targeting potential assessment of mucoadhesive chitosan nanoparticles designed for ulcerative colitis scintigraphy.

Raj P, Raj R, Kaul A, Mishra A, Ram A RSC Adv. 2022; 8(37):20809-20821.

PMID: 35542340 PMC: 9080856. DOI: 10.1039/c8ra01898g.

Curcumin and Its Modified Formulations on Inflammatory Bowel Disease (IBD): The Story So Far and Future Outlook.

Karthikeyan A, Young K, Moniruzzaman M, Beyene A, Do K, Kalaiselvi S Pharmaceutics. 2021; 13(4).

PMID: 33918207 PMC: 8065662. DOI: 10.3390/pharmaceutics13040484.

Curcumin suppresses intestinal microvascular endothelial cells invasion and angiogenesis induced by activated platelets.

Xu S, Xu Z, Yan S, Le J, Chen H, Ming L Exp Ther Med. 2019; 18(2):1099-1106.

PMID: 31316605 PMC: 6601414. DOI: 10.3892/etm.2019.7662.

References

Perner A, Andresen L, Normark M, Sorensen S, Eugen-Olsen J, Rask-Madsen J . Expression of nitric oxide synthases and effects of L-arginine and L-NMMA on nitric oxide production and fluid transport in collagenous colitis. Gut. 2001; 49(3):387-94. PMC: 1728426. DOI: 10.1136/gut.49.3.387. View

Monteleone G, Mann J, Monteleone I, Vavassori P, Bremner R, Fantini M . A failure of transforming growth factor-beta1 negative regulation maintains sustained NF-kappaB activation in gut inflammation. J Biol Chem. 2003; 279(6):3925-32. DOI: 10.1074/jbc.M303654200. View

Fan H, Qiu M, Mei J, Shen G, Liu S, Chen R . Effects of four regulating-intestine prescriptions on pathology and ultrastructure of colon tissue in rats with ulcerative colitis. World J Gastroenterol. 2005; 11(31):4800-6. PMC: 4398725. DOI: 10.3748/wjg.v11.i31.4800. View

Han S, Keum Y, Surh Y . Curcumin suppresses activation of NF-kappaB and AP-1 induced by phorbol ester in cultured human promyelocytic leukemia cells. J Biochem Mol Biol. 2002; 35(3):337-42. DOI: 10.5483/bmbrep.2002.35.3.337. View

Farrell R, Kelleher D . Glucocorticoid resistance in inflammatory bowel disease. J Endocrinol. 2003; 178(3):339-46. DOI: 10.1677/joe.0.1780339. View

Dong W, Liu S, Yu B, Wu D, Luo H, Yu J . Ameliorative effects of sodium ferulate on experimental colitis and their mechanisms in rats. World J Gastroenterol. 2003; 9(11):2533-8. PMC: 4656535. DOI: 10.3748/wjg.v9.i11.2533. View

Ukil A, Maity S, Karmakar S, Datta N, Vedasiromoni J, Das P . Curcumin, the major component of food flavour turmeric, reduces mucosal injury in trinitrobenzene sulphonic acid-induced colitis. Br J Pharmacol. 2003; 139(2):209-18. PMC: 1573841. DOI: 10.1038/sj.bjp.0705241. View

Furrie E, Macfarlane S, Cummings J, Macfarlane G . Systemic antibodies towards mucosal bacteria in ulcerative colitis and Crohn's disease differentially activate the innate immune response. Gut. 2003; 53(1):91-8. PMC: 1773925. DOI: 10.1136/gut.53.1.91. View

Jiang X, Cui H . A new chronic ulcerative colitis model produced by combined methods in rats. World J Gastroenterol. 2002; 6(5):742-746. PMC: 4688855. DOI: 10.3748/wjg.v6.i5.742. View

10.

Mitra S, Venkataranganna M, Sundaram R, Gopumadhavan S . Antioxidant activity of AO-8, a herbal formulation in vitro and in vivo experimental models. Phytother Res. 1999; 13(4):300-3. DOI: 10.1002/(SICI)1099-1573(199906)13:4<300::AID-PTR440>3.0.CO;2-A. View

11.

Ruby A, Kuttan G, Babu K, Rajasekharan K, Kuttan R . Anti-tumour and antioxidant activity of natural curcuminoids. Cancer Lett. 1995; 94(1):79-83. DOI: 10.1016/0304-3835(95)03827-j. View

12.

Singh S, Aggarwal B . Activation of transcription factor NF-kappa B is suppressed by curcumin (diferuloylmethane) [corrected]. J Biol Chem. 1995; 270(42):24995-5000. DOI: 10.1074/jbc.270.42.24995. View

13.

Jian Y, Mai G, Wang J, Zhang Y, Luo R, Fang Y . Preventive and therapeutic effects of NF-kappaB inhibitor curcumin in rats colitis induced by trinitrobenzene sulfonic acid. World J Gastroenterol. 2005; 11(12):1747-52. PMC: 4305867. DOI: 10.3748/wjg.v11.i12.1747. View

14.

Zhang F, Altorki N, Mestre J, Subbaramaiah K, Dannenberg A . Curcumin inhibits cyclooxygenase-2 transcription in bile acid- and phorbol ester-treated human gastrointestinal epithelial cells. Carcinogenesis. 1999; 20(3):445-51. DOI: 10.1093/carcin/20.3.445. View

15.

Aggarwal B, Kumar A, Bharti A . Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23(1A):363-98. View

16.

Jobin C, Bradham C, Russo M, Juma B, Narula A, Brenner D . Curcumin blocks cytokine-mediated NF-kappa B activation and proinflammatory gene expression by inhibiting inhibitory factor I-kappa B kinase activity. J Immunol. 1999; 163(6):3474-83. View

17.

Nikolaus S, Folscn U, Schreiber S . Immunopharmacology of 5-aminosalicylic acid and of glucocorticoids in the therapy of inflammatory bowel disease. Hepatogastroenterology. 2000; 47(31):71-82. View

18.

Barbosa D, Cecchini R, El Kadri M, Rodriguez M, Burini R, Dichi I . Decreased oxidative stress in patients with ulcerative colitis supplemented with fish oil omega-3 fatty acids. Nutrition. 2003; 19(10):837-42. DOI: 10.1016/s0899-9007(03)00162-x. View

19.

Pan M, Lin-Shiau S, Lin J . Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem Pharmacol. 2000; 60(11):1665-76. DOI: 10.1016/s0006-2952(00)00489-5. View